FS Development Corp (GMTX)

FINANCE: CORPORATE FINANCE
SIC: PHARMACEUTICAL PREPARATIONS

300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE, MA 02139

Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically de?ned age-related macular degeneration (AMD). Gemini's lead candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH), and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant. The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies.

Data as of 2021-08-02 09:15:32 -0400
Market Cap175.225 Million Shares Outstanding43.053 Million Avg 30-day Volume298.353 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.0 52-week High/Low19.09 / 4.06 Next Earnings Date Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from GMTX instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 0 0 (0.0%) 0 (0.0%)
Funds Holding: 50 36 38.89% 20 (1.17%) 23 (1.33%) -13.04%
13F shares: 25.847 Million 10.532 Million 145.43% 14.544 Million 8.034 Million 81.04%
% Ownership 60.2236 84.1414 -28.43% 33.8874 64.1841 -47.2%
New Positions: 26 15 73.33% 4 9 -55.56%
Increased Positions 11 2 450.0% 8 2 300.0%
Closed Positions 12 11 9.09% 7 9 -22.22%
Reduced Positions 8 7 14.29% 7 5 40.0%
Total Calls 382.612 Thousand 378.2 Thousand
Total Puts 85.809 Thousand 85.8 Thousand
PUT/CALL Ratio 0.22 0.23
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

FS Development Corp YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding GMTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding GMTX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MEYENBURG JASON PATRICK PRESIDENT & CEO

  • Officer
  • Director
 13,000 2021-05-14 3

PIEKOS BRIAN CHIEF FINANCIAL OFFICER

  • Officer
 7,655 2021-05-14 3

GEMAYEL GEORGES

  • Director
 0 2021-04-29 2

STRAPPS WALTER CHIEF SCIENTIFIC OFFICER

  • Officer
 9,000 2021-04-28 4

BARONE SAMUEL B. CHIEF MEDICAL OFFICER

  • Officer
 255,212 2021-04-12 2

LUBNER DAVID CHARLES

  • Director
 58,855 2021-03-12 3

ONG TUYEN

  • Director
 15,000 2021-03-12 3

LAUDER SCOTT CHIEF TECHNOLOGY OFFICER

  • Officer
 272,615 2021-02-23 3

REDMOND PRECILLIA CHIEF PEOPLE OFFICER

  • Officer
 25,489 2021-02-23 3

TANANBAUM JAMES B.

  • Director
 3,370,250 2021-02-05 3

FS DEVELOPMENT HOLDINGS, LLC

FORESITE CAPITAL FUND V, L.P.

FORESITE CAPITAL MANAGEMENT V, LLC

FORESITE CAPITAL OPPORTUNITY FUND V, L.P.

FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC

  • 10% Owner
  • DIRECTOR BY DEPUTIZATIONDIRECTOR BY DEPUTIZATIONDIRECTOR BY DEPUTIZATIONDIRECTOR BY DEPUTIZATIONDIRECTOR BY DEPUTIZATION
 4,870,250 2021-02-05 3

BELOFF GREGG CHIEF FINANCIAL OFFICER

  • Officer
 0 2021-02-05 1

UKNIS MARC CHIEF MEDICAL OFFICER

  • Officer
 277,117 2021-02-05 2

GORDON CARL L

  • Director
  • 10% Owner
 5,826,224 2021-02-05 1

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VI LLC

  • Director
  • 10% Owner
 5,826,224 2021-02-05 1

RHODES JASON P

  • Director
 5,254,365 2021-02-05 1

ATLAS VENTURE FUND X, L.P.

ATLAS VENTURE ASSOCIATES X, L.P.

ATLAS VENTURE ASSOCIATES X, LLC

ATLAS VENTURE OPPORTUNITY FUND I, L.P.

ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.

ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC

ATLAS VENTURE FUND XII, L.P.

ATLAS VENTURE ASSOCIATES XII, L.P.

ATLAS VENTURE ASSOCIATES XII, LLC

  • 10% Owner
 5,254,365 2021-02-05 1

GEORGE JEAN

  • Director
  • 10% Owner
 4,836,106 2021-02-05 1

LSV ASSOCIATES, LLC

LIGHTSTONE VENTURES, L.P.

LIGHTSTONE VENTURES (A), L.P.

LIGHTSTONE SINGAPORE, L.P.

LIGHTSTONE SINGAPORE ASSOCIATES, LLC

CARUSI MICHAEL A

PLAIN HENRY A JR

  • 10% Owner
 4,836,106 2021-02-05 1

FORESITE CAPITAL OPPORTUNITY FUND V, L.P.

FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC

  • 10% Owner
 441,500 2020-10-19 1

FS DEVELOPMENT HOLDINGS, LLC

FORESITE CAPITAL FUND V, L.P.

FORESITE CAPITAL MANAGEMENT V, LLC

TANANBAUM JAMES B. PRESIDENT & CEO

  • Officer
  • Director
  • 10% Owner
 441,500 2020-08-14 3

PAKIANATHAN DEEPIKA

  • Director
 0 2020-08-11 1

CAREY ROBERT

  • Director
 0 2020-08-11 1

DUBIN DANIEL

  • Director
 0 2020-08-11 1

RYAN DENNIS D CHIEF FINANCIAL OFFICER

  • Officer
 0 2020-08-11 1

FS DEVELOPMENT HOLDINGS, LLC

  • 10% Owner
 0 2020-08-11 3

ROME MICHAEL E VICE PRESIDENT

  • Officer
  • Director
 0 2020-08-11 1

BAJAJ VIKRAM

  • Director
 0 2020-08-11 1

FS DEVELOPMENT HOLDINGS, LLC

FORESITE CAPITAL FUND V, L.P.

FORESITE CAPITAL MANAGEMENT V, LLC

  • 10% Owner
 0 2020-08-11 1

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
GEMINI THERAPEUTICS INC GMTX 2021-08-05 22:15:04 UTC -0.5057 0.5857 90000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 21:45:03 UTC -0.5017 0.5817 90000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 21:15:03 UTC -0.5017 0.5817 90000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 20:45:03 UTC -0.5017 0.5817 90000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 20:15:04 UTC -0.5017 0.5817 90000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 19:45:04 UTC -0.5017 0.5817 90000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 19:15:03 UTC -0.5017 0.5817 90000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 18:45:03 UTC -0.5017 0.5817 90000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 18:15:03 UTC -0.5017 0.5817 90000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 17:45:03 UTC -0.5017 0.5817 90000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 17:15:03 UTC -0.5017 0.5817 90000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 16:45:02 UTC -0.5075 0.5875 90000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 16:15:03 UTC -0.5075 0.5875 90000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 15:45:03 UTC -0.5075 0.5875 90000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 15:15:02 UTC -0.5075 0.5875 95000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 14:45:02 UTC -0.5565 0.6365 95000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 14:15:04 UTC -0.5565 0.6365 95000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 13:45:04 UTC -0.5565 0.6365 95000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 13:15:03 UTC -0.5565 0.6365 95000
GEMINI THERAPEUTICS INC GMTX 2021-08-05 12:45:03 UTC -0.5565 0.6365 95000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments